Semaglutide

$80.00$185.00

Semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist, originally developed by Novo Nordisk to manage type 2 diabetes and later expanded for weight loss. It’s a once-weekly injectable (or daily oral option) that mimics the GLP-1 hormone, regulating blood sugar, appetite, and metabolism. Marketed as Ozempic (for diabetes), Wegovy (for weight loss), and Rybelsus (oral for diabetes), it’s become a cornerstone in metabolic health treatments due to its efficacy and safety profile.

 

SKU: N/A Category:
Description

Description

Primary Uses of Semaglutide

  1. Type 2 Diabetes Management:
    • Approved as Ozempic (FDA, 2017) and Rybelsus (2019), it lowers HbA1c (blood sugar average) by 1.5-2% at higher doses, enhancing insulin release and reducing glucagon (which raises blood sugar) in a glucose-dependent manner.
    • The SUSTAIN trials showed it outperforms older diabetes drugs like metformin or insulin in many cases.
  2. Weight Loss (Obesity Treatment):
    • Approved as Wegovy (FDA, June 2021) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with conditions like hypertension or diabetes.
    • In the STEP trials, patients lost 14.9% to 17.4% of body weight (up to 35-40 lbs) at 2.4 mg weekly after 68 weeks—significant but less than tirzepatide’s ~20%.
  3. Cardiovascular Benefits:
    • Reduces risk of major adverse cardiovascular events (e.g., heart attack, stroke) in type 2 diabetes patients with high risk, per the SUSTAIN-6 trial (2016). Ozempic carries an FDA indication for this.
    • Lowers blood pressure and lipids (e.g., triglycerides), aiding overall heart health.
  4. Potential Off-Label Uses:
    • Explored for fatty liver disease (MASLD) due to weight loss and metabolic effects, though not yet approved.
    • Anecdotal use for PCOS (polycystic ovary syndrome) to improve insulin resistance and weight.

How It Works

  • GLP-1 Action:
    • Appetite Suppression: Signals fullness to the brain, reducing food intake.
    • Slows Gastric Emptying: Keeps you full longer, stabilizing blood sugar.
    • Insulin Boost: Enhances glucose-dependent insulin secretion without causing hypoglycemia.
  • Its long half-life (~1 week) allows once-weekly dosing, unlike shorter-acting GLP-1 agonists (e.g., liraglutide).

How It’s Used

  • Administration:
    • Ozempic/Wegovy: Subcutaneous injection weekly (abdomen, thigh, or arm) via a pre-filled pen.
    • Rybelsus: Oral tablet daily (taken on an empty stomach with water, 30 minutes before food).

Product Usage: This item is designed exclusively for use as a research chemical in laboratory settings and in vitro experiments, to be handled only by licensed, trained professionals. It is not intended or approved for human or animal consumption. Any misuse, misbranding, or mislabeling as a drug, food, or cosmetic is strictly forbidden. All accompanying information is provided solely for educational purposes.

Additional information

Additional information

Milligrams

2.5MG

,

5MG

,

10MG